CardioScale provides on-site deterioration prediction for trauma victims. The companys solution helps save lives by enabling better triage and improved treatment prioritization decisions via its proprietary algorithm and portable cuff monitor, DTR8. CardioScale holds a worldwide patent for early shock diagnostics with a ready-to-use field monitor that measures all vital signs in addition to a proprietary cardiovascular reserve index (CVRI) to detect shock and preshock deterioration. The DTR8 measurement procedure is similar to that of a blood pressure test and provides comprehensive results in under 60 seconds. Measured indices are then calculated automatically using patented CVRI technology, and the results are transmitted wirelessly to a handheld device for review as well as displayed on the device itself. This numeric data can be used to evaluate the patients current condition as well as to provide a baseline for follow-up tests.